Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study

Abstract

Botulinum toxin (BTA) is a safe and effective therapeutic tool for many neurological conditions but few studies have investigated its real cost in neurological practice. We evaluated the daily cost of botulinum toxin type A (BTA) treatment through a cost effectiveness analysis alongside a prospective study of BTA injections at a French University Hospital over a 2-year follow-up period. The data of 3,108 BTA injections performed in 870 adult patients presenting with dystonia, facial hemispasm, or spasticity were entered in the database. Patients were questioned at each visit about the subjective effectiveness of the previous injection. The daily cost of BTA treatment was calculated as the ratio of each session’s cost (including all additional costs) to the duration of subjective efficacy. The subjective rating of efficacy duration was 17.3 ± 7.7 weeks for facial hemispasm, 15.4 ± 7.7 for blepharospasm, 14.3 ± 6.7 for cervical dystonia, 14.5 ± 7.8 and 14.1 ± 7.4 weeks for upper and lower limb spasticity, respectively. The daily cost of BTA injections was 0.57 ± 0.20 € for facial hemispasm, 0.95 ± 0.30 € for blepharospasm, 2.85 ± 0.86 € for cervical dystonia, 3.38 ± 1.49 € and 3.62 ± 1.81 € for upper and lower limb spasticity, respectively. When associated costs were considered, the daily cost of BTA injections was clearly increased (45–93%) in limb spasticity or rigidity but remained only modestly increased (15–37%) in other indications. These results obtained in a large cohort of patients show that BTA treatment has a low daily cost for a long-lasting effect, with a daily cost/benefit ratio that greatly depends on the indications.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Balkrishnan R, Camacho FT, Smith BP, Shilt JS, Jacks LK, Koman LA, Rascati KL, Mooney JF 3rd (2002) Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy. J South Orthop Assoc 11:71–79

    PubMed  Google Scholar 

  2. 2.

    Bodenez C, Bernat I, Willer JC, Barre P, Lamas G, Tankere F (2010) Facial nerve decompression for idiopathic Bell’s palsy: report of 13 cases and literature review. J Laryngol Otol 124:272–278

    Google Scholar 

  3. 3.

    Brefel-Courbon C, Simonetta-Moreau M, More C, Rascol O, Clanet M, Montastruc JL, Lapeyre-Mestre M (2000) A pharmacoeconomic evaluation of botulinum toxin in the treatment of spasmodic torticollis. Clin Neuropharmacol 23:203–207

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Cioni M, Esquenazi A, Hirai B (2006) Effects of botulinum toxin-A on gait velocity, step length, and base of support of patients with dynamic equinovarus foot. Am J Phys Med Rehabil 85:600–606

    PubMed  Article  Google Scholar 

  5. 5.

    Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev:CD004900

  6. 6.

    Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev:CD003633

  7. 7.

    Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005) Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev:CD004899

  8. 8.

    Dodel RC, Kirchner A, Koehne-Volland R, Kunig G, Ceballos-Baumann A, Naumann M, Brashear A, Richter HP, Szucs TD, Oertel WH (1997) Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 12:695–706

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Gudex CM, Hawthorne MR, Butler AG, Duffey PO (1997) Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis. Pharmacoeconomics 12:675–684

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Hung SW, Hamani C, Lozano AM, Poon YY, Piboolnurak P, Miyasaki JM, Lang AE, Dostrovsky JO, Hutchison WD, Moro E (2007) Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology 68:457–459

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M (2010) Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 26:1983–1992

    Google Scholar 

  12. 12.

    Kiss ZH, Doig-Beyaert K, Eliasziw M, Tsui J, Haffenden A, Suchowersky O (2007) The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain 130:2879–2886

    PubMed  Article  Google Scholar 

  13. 13.

    Lasalvia CG, Pereira Lde S, da Cunha MC, Kitadai SP (2006) Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm. Arq Bras Oftalmol 69:701–705

    PubMed  Article  Google Scholar 

  14. 14.

    Mitchell MP, Schaecher K, Cannon HE, Speckman M (2008) Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization. J Manag Care Pharm 14:442–450

    PubMed  Google Scholar 

  15. 15.

    Moro E, Piboolnurak P, Arenovich T, Hung SW, Poon YY, Lozano AM (2009) Pallidal stimulation in cervical dystonia: clinical implications of acute changes in stimulation parameters. Eur J Neurol 16:506–512

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Rodgers H, Shaw L, Price C, van Wijck F, Barnes M, Graham L, Ford G, Shackley P, Steen N (2008) Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Trials 9:59

    PubMed  Article  Google Scholar 

  17. 17.

    Ruiz FJ, Guest JF, Lehmann A, Davie AM, Guttler K, Schluter O, Dreiss G (2004) Costs and consequences of botulinum toxin type A use. Management of children with cerebral palsy in Germany. Eur J Health Econ 5:227–235

    PubMed  Article  Google Scholar 

  18. 18.

    Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM (2009) Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 182:2799–2804

    PubMed  Article  Google Scholar 

  19. 19.

    Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Sindou M, Keravel Y (2009) Neurosurgical treatment of primary hemifacial spasm with microvascular decompression. Neurochirurgie 55:236–247

    PubMed  Article  CAS  Google Scholar 

  21. 21.

    Ward A, Roberts G, Warner J, Gillard S (2005) Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 37:252–257

    PubMed  Article  Google Scholar 

  22. 22.

    Yelnik AP (2004) Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics. Ann Readapt Med Phys 47:575–589

    PubMed  CAS  Google Scholar 

  23. 23.

    Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq P, Dehail P, Quentin V, Marque P, Parratte B, Pellas F, Rousseaux M, Trocello JM, Uzzan M, Dumarcet N (2009) Drug treatments for spasticity. Ann Phys Rehabil Med 52:746–756

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Professor M.C. Saux and Dr. M. Bonin who managed the supply of Botulinum toxin in the Bordeaux hospital pharmacy as well as R. Cooke for his comments on the manuscript.

Conflict of interest

The Bordeaux University Hospital funded the study in the context of an audit of good professional practice. All authors declare (1) no support from any company for the submitted work; (2) no relationships with any companies that might have an interest in the submitted work in the previous 3 years; (3) no nonfinancial interests that may be relevant to the submitted work.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Pierre Burbaud.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Burbaud, P., Ducerf, C., Cugy, E. et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol 258, 1670–1675 (2011). https://doi.org/10.1007/s00415-011-5998-9

Download citation

Keywords

  • Botulinum toxin
  • Dystonia
  • Spasticity
  • Cost effectiveness study